[PDF] psu.edu

[PDF][PDF] Older age may associate with better therapeutic effect of gefitinib in non-small cell lung cancer

GC Chang, YTY CK, SH Lin - J Chin Oncol Soc, 2008 - Citeseer
… response to gefitinib (ORR: 40%). After stepwise logistics model of our study, gefitinib offered
better … In our study, there is a trend of increasing response to gefitinib with increasing age, …
被引用次数：2 相关文章

Gefitinib plus Fuzheng Kang'ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a …

X Yang, X Chai, W Wu, S Long, H Deng, Z Pan… - Chinese journal of …, 2018 - Springer
… (3) Gefitinib and erlotinib are the first small molecule tyrosine … The most common toxic effects
in the GF group and G group … in patients with EGFR mutation while treated with gefitinib plus …
被引用次数：22 相关文章 所有 9 个版本

新穎HDAC 抑制劑治療具Gefitinib 抗藥性之非小細胞肺癌之研究

CH Weng - 國立臺灣大學藥理學研究所學位論文, 2013 - airitilibrary.com
… ) is found in NSCLC and occurs more frequent in East Asia countries. EGFR-tyrosine kinase
inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have exhibited superior outcomes …
相关文章

尋找第二代EGFR 抑制劑的新作用標的與其作用機制之探討

HF Tu - 臺灣大學生物化學暨分子生物學研究所學位論文, 2016 - airitilibrary.com
… (TKIs, eg, Iressa and Tarceva) against EGFR are commonly used for the cancer treatment. …
-EGFR treatment and the etiology for the drug resistance is frequently due to EGFR mutations …
相关文章

新穎HDAC 抑制劑治療具Gefitinib 抗藥性之非小細胞肺癌之研究

翁千惠 - 2013 - tdr.lib.ntu.edu.tw
… ) is found in NSCLC and occurs more frequent in East Asia countries. EGFR-tyrosine kinase
inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have exhibited superior outcomes …
相关文章

[引用][C] Efficacy of gefitinib, erlotinib and icotinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation

RN Cong, F Gu, B Wang - J Mod Oncol, 2018
被引用次数：1 相关文章

尋找第二代EGFR 抑制劑的新作用標的與其作用機制之探討

涂馨方 - 2016 - tdr.lib.ntu.edu.tw
… (TKIs, eg, Iressa and Tarceva) against EGFR are commonly used for the cancer treatment. …
-EGFR treatment and the etiology for the drug resistance is frequently due to EGFR mutations …
相关文章

[引用][C] Analysis of EGFR mutations in non-small cell lung cancer in Nanning Guangxi China

Y Tang, L Zhang, X Tan - J Modern Oncol, 2014
被引用次数：3 相关文章

[引用][C] Revisiting squamous cell carcinoma of the lungs–a disease given less attention

YM Chen, JF Shih, CM Tsaim, YC Lee, RP Perng… - J Chin Oncol Soc, 2009
被引用次数：3 相关文章

[引用][C] The value analysis of blood brain barrier permeability in the treatment of multiple brain metastases patients with non-small cell lung cancer

Z Yongli, D Jigang, L Bo, L Maojiang, C Yan… - J. Mod. Oncol, 2017
被引用次数：1 相关文章